Hepatitis C

The hepatitis C virus (HCV) is one of the most important causes of chronic liver disease in the United States. It accounts for about 15 percent of acute viral hepatitis, 60 to 70 percent of chronic hepatitis, and up to 50 percent of cirrhosis, end-stage liver disease, and liver cancer. Of the U.S. population, 1.6 percent, or an estimated 4.1 million Americans, have antibody to HCV (anti-HCV), indicating ongoing or previous infection with the virus.

Facts and Stats about Hepatitis C: courtesy of WebMD

Current Hepatitis Medications Available

  • Epclusa is the first 12 weeks treatment for all genotypes of hepatitis C (1-6) infection in patients with or without cirrhosis regardless of prior Hep C treatment experience. This is a breakthrough therapy to those infected w/ genotype 2 and 3 that is a one pill once a day therapy. Cure Rate: genotype 1 - 98%, 2- 99%, 3- 95%, 4- 100%, 5- 97%, 6-100%.
  • Daklinza (taken w/ Sovaldi) is a 1 pill a day treatment for hepatitis C genotype 1 & 3 infection that is taken w/ Sovaldi. Cure rate of over 90% in patient with or without cirrhosis or any post transplant patients. 
  • Sovaldi
  • Zepatier treats genotype 1 and 4, particularly a good option for patient that cannot stop their PPIs (proton pump inhibitor) such as Nexium, Protonix, Prevacid, Dexilant, etc.
  • Harvoni
  • Viekira Pak/XR 
  • Technivie